From the clip:
“We are excited to test sozinibercept in large P3 programmes […] with the goal of […] showing that we can improve visual acuity hopefully by up to 5 letters or more.“
To my memory, this is the first time somebody sharing responsibility for running the trials dares to explicitly mention a „5 letters or more“ improvement as what OPT internally is really hoping for. If this hope materializes then Eichenbaum is absolutely right saying that sozinibercept would disrupt the wAMD market.
I just cannot believe existing players continuing to stay quiet with this disruptive opportunity being up for sale / partnership just 15 months ahead of P3 results. Therefore, I’d indeed expect a partnership occurring over the next 3 months being more probable than a classic CR.
- Forums
- ASX - By Stock
- Ann: Opthea to Host Key Opinion Leader Event on April 3, 2024
From the clip:“We are excited to test sozinibercept in large P3...
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add OPT (ASX) to my watchlist
(20min delay)
|
|||||
Last
34.5¢ |
Change
0.005(1.47%) |
Mkt cap ! $376.5M |
Open | High | Low | Value | Volume |
34.0¢ | 35.0¢ | 33.5¢ | $986.8K | 2.875M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 55705 | 34.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
35.0¢ | 29727 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 55705 | 0.345 |
6 | 90470 | 0.340 |
12 | 690659 | 0.335 |
12 | 265201 | 0.330 |
7 | 303294 | 0.325 |
Price($) | Vol. | No. |
---|---|---|
0.350 | 29727 | 1 |
0.355 | 8000 | 1 |
0.360 | 29900 | 2 |
0.365 | 45000 | 1 |
0.370 | 174576 | 2 |
Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
Featured News
OPT (ASX) Chart |